Physician profile
Destiny Smith
NPI 1306506837
$1,484.36
in general payments reported to CMS, 2019-2025
13 companies · $706 in 2025
The $706 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $80.12 · 2023: $364 · 2024: $335 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $447.39 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $308.42 | 2023-2025 | Slynd, Twirla |
| Sumitomo Pharma America, INC. | $237.20 | 2023-2024 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $127.17 | 2024-2025 | |
| Abbvie INC. | $72.26 | 2022-2023 | |
| Organon LLC | $68.74 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $56.24 | 2025 | Qelbree |
| Boston Scientific Corporation | $51.38 | 2023 | Superion Indirect Decompression System |
| Myovant Sciences INC. | $40.13 | 2022 | |
| Astellas Pharma US INC | $21.32 | 2024 | Veozah |
| Daiichi Sankyo INC. | $19.21 | 2023 | Injectafer |
| Hologic Sales and Service, LLC | $18.89 | 2025 | Aptima |
| Medline Industries Lp | $16.01 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Destiny Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.